Nasdaq Sees Continued Momentum in U.S. Listings with Record-Breaking Exchange Transfers and Improved IPO Environment
Record number of transfers valued at $379.8 billion market cap joining Nasdaq from NYSE in 2017
Leading U.S. exchange in total number of IPOs for 16 consecutive quarters
NEW YORK, Dec. 20, 2017 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq:NDAQ) announced today that it welcomed a total of 262 new listings so far in 2017 - including 133 initial public offerings (IPOs) and 33 transfers. The record-breaking year of exchange transfers is a validation of our long-term commitment to listed companies across all sectors at any stage of their growth journeys. Nasdaq has extended its IPO leadership to 16 consecutive quarters in the U.S. with a 62 percent win rate. Notable IPOs in 2017 included Roku, Redfin, CarGurus, National Vision, Denali and Hamilton Lane.
This year, the total market value of all companies joining Nasdaq from the NYSE since 2005 has exceeded $1.2 trillion dollars. In 2017, Nasdaq welcomed a total of 33 switches, including 12 companies and 21 exchange traded products (ETPs), with a combined market value of approximately $379.8 billion. Company transfers included PepsiCo, Inc. ($165.8B market cap), Principal Financial Group ($20.6B market cap), Workday ($21.8B market cap), Brookfield Property Partners ($15.4B market cap), Xcel Energy ($25.7B market cap) and Visteon ($4B market cap). PepsiCo is the largest exchange switch to date.
Maintaining its position as the leading global listing venue, companies from a diverse range of industries and countries successfully launched their IPOs on Nasdaq in 2017, raising a total of approximately $15.1 billion. Nine of the top 10 best performing U.S. IPOs chose Nasdaq as their home exchange as well as 8 of the top 10 performing technology IPOs (as of the market close on December 15, 2017).
Nasdaq Weighted IPO Return 2017
Data source: Nasdaq, as of market close on December 15, 2017
"Since 1971, Nasdaq has supported many of the world's most innovative and admired companies and we couldn't be more proud to be the long-term partner throughout all stages of their journeys - before, during and after the IPO," said Nelson Griggs, President, Nasdaq Stock Exchange. "This year, we welcome the next generation of entrepreneurs and some of the most recognized global brands to the Nasdaq family, while celebrating milestones of Nasdaq listed companies including Amazon, Starbucks and Celgene. Their achievements are the cornerstone of our nation's economic growth, delivering breakthrough innovations in technology, medicine, entertainment and all areas that impact our daily life."
Companies celebrating their listing milestones include:
- Amazon.com, Inc. (ticker: AMZN) - listed on May 16, 1997, celebrating its 20th listing anniversary. The stock opened at $18 per share in 1997 and is trading above $1,000 today.
- Starbucks Corporation (ticker: SBUX) - listed on July 2, 1992, celebrating its 25th listing anniversary. Since its listing on Nasdaq, it grew from 165 stores to over 26,000 global locations.
- Celgene Corp. (ticker: CELG) - listed on August 7, 1987, celebrating its 30th listing anniversary. There are more than 300 clinical trials at major medical centers using compounds from Celgene.
- Netflix, Inc. (ticker: NFLX) - listed on May 23, 2002, celebrating 15th listing anniversary. Founded in 1997, Netflix was a video mailing service. Today Netflix reaches 100 million subscribers globally and transforms the entertainment industry with its original content.
|2017 Total New Listings*||262|
|Initial Public Offerings**||133|
|ETPs (including ETP transfers)||61|
|Company Transfers to Nasdaq from Competing Exchanges***||12|
*Data source: Nasdaq, FactSet, EDGAR Online, January 1, 2017 - December 15, 2017
**Includes the following capital raising events in the U.S. as priced in 2017: IPO, REIT, SPAC, BDC, Foreign Exchange Dual Listing, Best Effort and Spin-offs
***Includes all transfers announced as of December 19, 2017
The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Information about the company is provided by the company or comes from the company's public filings and is not independently verified by Nasdaq. Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.
Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $12 trillion. To learn more, visit: http://business.nasdaq.com.
Media Relations Contact:
+ Stephanie Lowenthal
+ (646) 441-5073
|+ Emily Pan
+ (646) 441-5120
- NDAQG -
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nasdaq via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 28, 201817.7.2018 22:30 | Pressmeddelande
LYON, France and CAMBRIDGE, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP) announced that its 2018 Annual General Meeting was held in Lyon on Thursday, June 28, 2018. At the meeting, all resolutions for which management recommended a vote in favor, were adopted, including: - Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2017 and quietus of directors; - Allocation of the financial year's results; - Approval of regulatory agreements and commitments referred to in Article L.225-38 of the French Commercial Code; - Approval of the regulations of the share subscription and/or purchase options plan adopted by the Board of Directors on June 27, 2017; - Authorization for the Board of Directors to grant share subscription and/or share purchase options and/or to issue detachable share subscription warrants to corporate officers and employees of the Company or companies in the ERYTECH Pharma
Williams Scotsman Receives Competition Bureau Clearance for ModSpace Acquisition17.7.2018 22:15 | Pressmeddelande
BALTIMORE, July 17, 2018 (GLOBE NEWSWIRE) -- WillScot Corporation (NASDAQ:WSC) ("Williams Scotsman"), a specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that, on July 16, 2018, the Canadian Competition Bureau issued a No Action Letter relating to Williams Scotsman's proposed acquisition of Modular Space Corporation ("ModSpace"). WillScot has now obtained the regulatory approvals required to complete the acquisition and continues to progress towards closing in the third quarter of 2018. About Williams Scotsman Headquartered in Baltimore, Maryland, WillScot Corporation is the public holding company for the Williams Scotsman family of companies in the United States, Canada and Mexico. WillScot Corporation trades on the NASDAQ stock exchange under the ticker symbol "WSC." Williams Scotsman is a specialty rental services market leader providing innovative modular space and portable storage solutio
Minerva Neurosciences Elects Jeryl Hilleman to Board of Directors17.7.2018 22:05 | Pressmeddelande
WALTHAM, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the election of Jeryl Hilleman to the Board of Directors of the Company. "Jeri brings a broad life sciences background to Minerva that includes high growth commercial biopharma, med-tech and data science companies," said William F. Doyle, Lead Independent Director of Minerva. "Her track record of delivering strategic and financial growth through execution, strategic partnering and multiple acquisitions will serve Minerva well as the Company completes five ongoing late-stage clinical trials with roluperidone, seltorexant and MIN-117." Ms. Hilleman is presently Chief Financial Officer of Intersect ENT (NASDAQ:XENT), a medical device company with commercial products for the treatment of chronic sinusitis. Previously, she served as CFO of several public
Orion Biotechnology Awarded a $2M Grant from National Center for Research and Development to Fund Further Development of its HIV Microbicide17.7.2018 21:00 | Pressmeddelande
OTTAWA, July 17, 2018 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced that its European subsidiary, Orion Biotechnology Polska Sp. z o.o., was awarded a grant of $2M US dollars by the National Center for Research and Development . The grant will fund a project to advance development of the company's innovative microbicide candidate (OB-002H). Designed to prevent the transmission of HIV, OB-002H has the potential to address an urgent and growing need for an HIV prevention product that is affordable, appealing to use, and easily integrates into the lifestyles of people at risk for HIV infection regardless of age, sex or gender. The project is co-financed by the National Center for Research and Development under the InnoNeuroPharm program - Measure 1.2: Sectoral R & D programs of the Intelligent Development Operational Program 2014-2020. Orion Biotechnology will use the grant to complete IND enabling studies, advance OB-002H to
Greater Anglia Selects PowerPlan to Optimise Its Asset Investments17.7.2018 15:29 | Pressmeddelande
ATLANTA, July 17, 2018 (GLOBE NEWSWIRE) -- Greater Anglia, a UK-based train operating company, has selected PowerPlan's Asset Investment Optimization software suite to maximise its asset investments over a 40-year time period. Greater Anglia's long-term investment strategy includes a 40-year asset plan to meet its regulatory requirements. For what was historically built with manual processes and not easily tracked, the Asset Investment Optimization solution from PowerPlan will provide a comprehensive, auditable approach to help the company analyze different investment scenarios for impacts to risk, cost, timing and level of service and provide a defendable asset plan for the next four decades. "The condition of our assets drives our business," said Richard Turner, Head of Asset Management for Greater Anglia. "With PowerPlan, we can apply a fact-based methodology to prioritise investments, maximise their return and produce plans that communicate our asset strategy to internal and extern
Oxford Immunotec Schedules Second Quarter 2018 Earnings Release and Conference Call for July 31, 201817.7.2018 14:30 | Pressmeddelande
OXFORD, United Kingdom and MARLBOROUGH, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that it plans to release second quarter 2018 financial results prior to market open on Tuesday, July 31, 2018. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a conference call to review the Company's results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers or +1 (484) 365-2897 for international callers and reference confirmation code 9268558, approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at www.oxfordimmunotec.com. The replay will be available on the Company's website for approximately
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum